Definium Therapeutics (NASDAQ:DFTX) Price Target Raised to $90.00 at JonesTrading

Definium Therapeutics (NASDAQ:DFTX) had its target price increased by stock analysts at JonesTrading from $74.00 to $90.00 in a research note issued to investors on Thursday,Benzinga reports. The firm currently has a “buy” rating on the stock. JonesTrading’s target price suggests a potential upside of 103.94% from the company’s current price.

Several other brokerages have also weighed in on DFTX. Citigroup reissued a “buy” rating on shares of Definium Therapeutics in a research report on Monday, June 22nd. Stifel Nicolaus increased their price target on shares of Definium Therapeutics from $30.00 to $60.00 and gave the company a “buy” rating in a research note on Wednesday, July 8th. Weiss Ratings reissued a “sell (d-)” rating on shares of Definium Therapeutics in a report on Friday, July 17th. Canaccord Genuity Group set a $64.00 target price on shares of Definium Therapeutics and gave the company a “buy” rating in a report on Thursday. Finally, Wells Fargo & Company increased their target price on shares of Definium Therapeutics from $68.00 to $72.00 and gave the company an “overweight” rating in a research report on Thursday. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $62.69.

Definium Therapeutics Stock Up 3.1%

Shares of DFTX stock traded up $1.34 on Thursday, reaching $44.13. 1,290,696 shares of the stock were exchanged, compared to its average volume of 2,293,201. The company has a market capitalization of $4.40 billion, a price-to-earnings ratio of -12.87 and a beta of 2.23. The business’s 50 day moving average price is $39.06 and its 200 day moving average price is $26.52. The company has a current ratio of 6.95, a quick ratio of 6.95 and a debt-to-equity ratio of 0.04. Definium Therapeutics has a twelve month low of $8.70 and a twelve month high of $49.70.

Definium Therapeutics (NASDAQ:DFTX) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($1.44) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.89). As a group, sell-side analysts expect that Definium Therapeutics will post -2.81 earnings per share for the current fiscal year.

Insider Activity at Definium Therapeutics

In other news, insider Mark Sullivan sold 13,008 shares of Definium Therapeutics stock in a transaction on Thursday, June 25th. The stock was sold at an average price of $45.03, for a total transaction of $585,750.24. Following the completion of the transaction, the insider owned 320,571 shares of the company’s stock, valued at $14,435,312.13. The trade was a 3.90% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO Robert Barrow sold 29,208 shares of the business’s stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $45.03, for a total transaction of $1,315,236.24. Following the completion of the sale, the chief executive officer owned 1,098,246 shares in the company, valued at $49,454,017.38. This represents a 2.59% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 48,096 shares of company stock valued at $2,165,763. 2.40% of the stock is currently owned by corporate insiders.

Institutional Trading of Definium Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of DFTX. Royal Bank of Canada boosted its stake in shares of Definium Therapeutics by 10.4% during the first quarter. Royal Bank of Canada now owns 65,237 shares of the company’s stock valued at $382,000 after acquiring an additional 6,148 shares during the last quarter. Creative Planning raised its stake in Definium Therapeutics by 2.6% in the 2nd quarter. Creative Planning now owns 66,097 shares of the company’s stock valued at $429,000 after purchasing an additional 1,655 shares during the last quarter. JPMorgan Chase & Co. lifted its holdings in Definium Therapeutics by 5.1% in the 2nd quarter. JPMorgan Chase & Co. now owns 48,487 shares of the company’s stock valued at $315,000 after purchasing an additional 2,342 shares in the last quarter. Rhumbline Advisers lifted its holdings in Definium Therapeutics by 6.3% in the 2nd quarter. Rhumbline Advisers now owns 115,296 shares of the company’s stock valued at $748,000 after purchasing an additional 6,839 shares in the last quarter. Finally, Russell Investments Group Ltd. boosted its stake in shares of Definium Therapeutics by 110.4% during the 2nd quarter. Russell Investments Group Ltd. now owns 3,817 shares of the company’s stock worth $25,000 after purchasing an additional 2,003 shares during the last quarter. Hedge funds and other institutional investors own 27.91% of the company’s stock.

Key Stories Impacting Definium Therapeutics

Here are the key news stories impacting Definium Therapeutics this week:

• Positive Sentiment: Definium reported positive topline results from the Phase 3 Voyage study. DT120 ODT produced a 5.4-point improvement versus placebo on the Hamilton Anxiety Rating Scale, strengthening the case for the therapy’s efficacy and potential regulatory and commercial value. Definium says LSD-based pill reduces anxiety in late-stage study
• Positive Sentiment: The results represent the second positive Phase 3 study for DT120, prompting reports that the drug could potentially disrupt the anxiety-treatment market. The data also support investor expectations for DT120 in more than one indication and a possible catalyst in September 2026. Definium Therapeutics Announces Positive Topline Results
• Positive Sentiment: Several firms raised their price targets and maintained bullish ratings: Robert W. Baird lifted its target to $75 with an “outperform” rating, Wells Fargo raised its target to $72 with an “overweight” rating, and RBC increased its target to $66 while also rating the stock “outperform.” Needham separately raised its target to $66 and kept a “buy” rating. These targets imply substantial potential upside from the stock’s recent level near $44. Analyst price-target changes
• Neutral Sentiment: Trading in DFTX was temporarily halted for news pending on August 12, highlighting the market-moving nature of the clinical announcement. The stock is trading close to its 52-week high, which may increase volatility as investors assess the data and upcoming regulatory milestones.
• Negative Sentiment: Definium remains loss-making, and HC Wainwright reduced its EPS forecasts across 2026–2030, including lowering its 2026 estimate to a $3.05 loss per share and its 2028 estimate to $0.33 from $0.77. The company’s earlier quarterly loss also missed consensus, leaving execution, cash requirements and commercialization risks as important counterweights to the positive trial results.

Definium Therapeutics Company Profile

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.